Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension
- PMID: 16284232
- DOI: 10.1152/ajpheart.00885.2005
Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension
Abstract
It has long been proposed that the renin-angiotensin system exerts a stimulatory influence on the sympathetic nervous system, including augmentation of central sympathetic outflow and presynaptic facilitation of norepinephrine release from sympathetic nerves. We tested this proposition in 19 patients with essential hypertension, evaluating whether the angiotensin receptor blockers (ARBs) eprosartan and losartan had identifiable antiadrenergic properties. This was done in a prospective, randomized, three-way placebo-controlled study of crossover design. Patients were randomized to 600 mg of eprosartan daily, 50 mg of losartan daily, or placebo. The treatment period was 4 wk, with 2-wk washout periods. Multiunit firing rates in efferent sympathetic nerves distributed to skeletal muscle vasculature (muscle sympathetic nerve activity, MSNA) were measured with microneurography, testing whether ARBs inhibit central sympathetic outflow. In parallel, isotope dilution methodology was used to measure whole body norepinephrine spillover to plasma. Mean blood pressure on placebo was 151/98 mmHg, with both ARBs causing reductions of approximately 11 mmHg systolic and 6 mmHg diastolic pressure, placebo corrected. Both MSNA [35 +/- 12 bursts/min (mean +/- SD) on placebo] and whole body norepinephrine spillover [366 +/- 247 ng/min] were unchanged by ARB administration, indicating that the ARBs did not materially inhibit central sympathetic outflow or act presynaptically to reduce norepinephrine release at existing rates of nerve firing. These findings contrast with the easily demonstrable reduction in sympathetic nervous activity produced by antihypertensive drugs of the imidazoline-binding class, which are known to act within the brain to inhibit sympathetic nervous outflow. We conclude that sympathetic nervous inhibition is not a major component of the blood pressure-lowering action of ARBs in essential hypertension.
Similar articles
-
Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.J Am Soc Nephrol. 2004 Nov;15(11):2902-7. doi: 10.1097/01.ASN.0000143471.10750.8C. J Am Soc Nephrol. 2004. PMID: 15504943 Clinical Trial.
-
Elevation of sympathetic activity by eprosartan in young male subjects.Am J Hypertens. 2003 Aug;16(8):658-64. doi: 10.1016/s0895-7061(03)00917-8. Am J Hypertens. 2003. PMID: 12878372 Clinical Trial.
-
Differentiation in the effects of the angiotensin II receptor blocker class on autonomic function.J Hypertens Suppl. 2002 Jun;20(5):S13-9. J Hypertens Suppl. 2002. PMID: 12184059 Review.
-
Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.J Hypertens Suppl. 1999 Jun;17(2):S27-32. J Hypertens Suppl. 1999. PMID: 10465064 Review.
-
Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.Pharmacology. 1997 Nov;55(5):244-51. doi: 10.1159/000139534. Pharmacology. 1997. PMID: 9399334
Cited by
-
The association between sleep duration and muscle sympathetic nerve activity.Clin Auton Res. 2023 Dec;33(6):647-657. doi: 10.1007/s10286-023-00965-7. Epub 2023 Aug 6. Clin Auton Res. 2023. PMID: 37543558 Free PMC article.
-
Neurogenic Hypertension, the Blood-Brain Barrier, and the Potential Role of Targeted Nanotherapeutics.Int J Mol Sci. 2023 Jan 22;24(3):2213. doi: 10.3390/ijms24032213. Int J Mol Sci. 2023. PMID: 36768536 Free PMC article. Review.
-
Cardiovascular medication seems to promote recovery of autonomic dysfunction after stroke.J Neurol. 2022 Oct;269(10):5454-5465. doi: 10.1007/s00415-022-11204-w. Epub 2022 Jun 12. J Neurol. 2022. PMID: 35690694 Free PMC article.
-
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment.Hypertension. 2022 Apr;79(4):827-835. doi: 10.1161/HYPERTENSIONAHA.121.18348. Epub 2022 Jan 20. Hypertension. 2022. PMID: 35045722 Free PMC article. Clinical Trial.
-
Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications.Cardiovasc Diabetol. 2021 Aug 19;20(1):170. doi: 10.1186/s12933-021-01356-w. Cardiovasc Diabetol. 2021. PMID: 34412646 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical